other material
confidence high
sentiment positive
materiality 0.85
NAMS: Phase 3 BROOKLYN trial of obicetrapib meets primary endpoint; LDL-C down 36.3% at day 84
NewAmsterdam Pharma Co N.V.
- LDL-C reduced 36.3% vs placebo at day 84 and 41.5% at day 365, both p<0.0001.
- 51% of patients on obicetrapib achieved LDL-C below 70 mg/dL.
- Safety comparable to placebo; TEAEs 63.7% vs 70.3%, discontinuation 7.6% vs 14.4%.
- Mean baseline LDL-C was 123 mg/dL despite 79% on high-intensity statins.
- Next data readouts: BROADWAY (Q4 2024) and TANDEM (Q1 2025).